Pharmaceutical

FDA approves Johnson & Johnson’s TREMFYA for ulcerative colitis

Johnson & Johnson has announced that the US FDA has approved TREMFYA for the treatment of active ulcerative colitis (UC).

Sep 12, 2024 - 04:00
FDA approves Johnson & Johnson’s TREMFYA for ulcerative colitis
Johnson & Johnson has announced that the US FDA has approved TREMFYA for the treatment of active ulcerative colitis (UC).
Read the original article

Tags:

Previous Article

FDA grants breakthrough therapy designation to Neuraptive’s NTX-001

Next Article

EASD 2024: Are tetra-agonists the future of metabolic diseases treatment?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NS Pharma gains EC orphan drug designation to treat EGPA

NS Pharma gains EC orphan drug designation to treat EGPA

Jan 23, 2024

Randomized controlled trials are the ‘gold standard’ of research — but a difficult fit for trans care

Randomized controlled trials are the ‘gold standard’ of...

Sep 16, 2023

STAT+: Study finds supplements of amino acid taurine slow aging in mice and monkeys

STAT+: Study finds supplements of amino acid taurine sl...

Jun 8, 2023